MK-4827 (Niraparib): Selective PARP-1/-2 Inhibitor for BRCA-Mutant Cancer Research

Executive Summary: MK-4827 (Niraparib) is a potent and selective oral PARP-1/-2 inhibitor with nanomolar IC₅₀ values (3.8 nM for PARP-1, 2.1 nM for PARP-2) and is widely used in DNA repair pathway research, particularly for BRCA-mutant cancers (APExBIO). It acts by competitively inhibiting the NAD⁺ binding site of PARP enzymes, thus impairing DNA repair and inducing synthetic lethality in homologous recombination-deficient (HRD) cells (olaparib.net). MK-4827 demonstrates high selectivity, sparing normal epithelial cells at micromolar concentrations. In vivo studies confirm its efficacy in tumor xenograft models and its ability to potentiate radiotherapy with minimal toxicity (3xflag.com). The compound is produced and distributed by APExBIO (SKU: A3617) and is integral to translational DNA damage response research.

Biological Rationale

Poly(ADP-ribose) polymerases (PARPs) are a family of nuclear enzymes involved in detecting DNA single-strand breaks and catalyzing poly(ADP-ribosyl)ation using NAD⁺ as a substrate (APExBIO). PARP-1 and PARP-2 are essential for base excision repair (BER) and maintaining genomic integrity. Inhibition of these enzymes leads to the accumulation of unrepaired DNA lesions, particularly lethal in cells deficient in homologous recombination repair, such as those harboring BRCA1 or BRCA2 mutations (olaparib.net). This synthetic lethality is the key rationale for using selective PARP inhibitors like MK-4827 in targeted cancer therapy research. The enhanced DNA damage response and repair pathway inhibition is leveraged to selectively eliminate tumor cells while sparing normal tissues. MK-4827’s selectivity and potency make it an important tool for understanding the interplay of DNA repair mechanisms and for preclinical development of anticancer strategies, including radiosensitization (pci32765.com).

Mechanism of Action of MK-4827 (Niraparib), a potent and selective PARP-1/-2 inhibitor

MK-4827 (Niraparib) is an orally bioavailable small molecule inhibitor with a molecular weight of 320.39 (C₁₉H₂₀N₄O). It binds competitively at the NAD⁺ site of PARP-1 and PARP-2, blocking their enzymatic activity (APExBIO). This prevents poly(ADP-ribosyl)ation of proteins, a post-translational modification crucial for DNA damage signaling and repair. The inhibition is highly selective, with IC₅₀ values of 3.8 nM (PARP-1) and 2.1 nM (PARP-2); no significant inhibition of other PARP family members or unrelated enzymes has been observed under similar conditions (olaparib.net). By inhibiting PARP, MK-4827 leads to accumulation of DNA single-strand breaks, which collapse into double-strand breaks during replication. In HR-deficient cells (e.g., BRCA1/2 mutant), this results in cell death, whereas normal cells with intact homologous recombination can compensate (3xflag.com). The compound also reduces intracellular NAD⁺ levels, further sensitizing tumor cells to DNA damage (Mei et al., 2025).

Evidence & Benchmarks

• MK-4827 (Niraparib) exhibits nanomolar antiproliferative activity (CC₅₀: 10–100 nM) in BRCA-1 and BRCA-2 mutant cancer cell lines (APExBIO).
• Normal human prostate and mammary epithelial cells resist MK-4827 cytotoxicity at micromolar concentrations (>1,000 nM), demonstrating high selectivity (olaparib.net).
• In vivo, MK-4827 enhances survival and tumor regression in BRCA-1 mutant MDA-MB-436 xenograft models at oral doses, with minimal body weight loss and no overt toxicity (3xflag.com).
• MK-4827 potentiates the effects of radiotherapy in lung and breast cancer xenograft models, increasing DNA double-strand break markers (γH2AX) post-irradiation (pci32765.com).
• In platinum-resistant ovarian cancer models, combination with all-trans retinoic acid (ATRA) reverses PARP inhibitor resistance and suppresses tumor growth both in vitro and in vivo (Mei et al., 2025).

This article extends prior overviews by providing quantified selectivity data, updated resistance management strategies, and detailed workflow parameters, complementing the broader mechanistic insights discussed in MK-4827 (Niraparib): Selective PARP-1/-2 Inhibitor for BR....

Applications, Limits & Misconceptions

MK-4827 is widely used in preclinical cancer research to:

• Model synthetic lethality in BRCA-1 and BRCA-2 mutant cancers (olaparib.net).
• Investigate DNA repair pathway inhibition and homologous recombination deficiency (HRD) mechanisms (3xflag.com).
• Potentiate the cytotoxicity of chemoradiotherapy in tumor xenograft models (pci32765.com).

However, limitations exist:

• PARP inhibitor resistance can develop after prolonged exposure, particularly following platinum-based chemotherapy (Mei et al., 2025).
• Efficacy is reduced in homologous recombination-proficient (HRP) and BRCA wild-type tumors (olaparib.net).
• Not all mechanisms of resistance are fully elucidated, necessitating combination strategies (e.g., with ATRA) to restore sensitivity (Mei et al., 2025).

Common Pitfalls or Misconceptions

• MK-4827 is not effective in all tumor types; activity is highest in BRCA-1/-2 mutant and HR-deficient backgrounds (olaparib.net).
• Resistance to one PARP inhibitor may not predict pan-resistance to all PARPis (Mei et al., 2025).
• MK-4827 is insoluble in water; improper solubilization can compromise experimental reproducibility (APExBIO).
• Long-term storage of solutions at room temperature or repeated freeze-thaw cycles can degrade MK-4827 (APExBIO).

Workflow Integration & Parameters

MK-4827 is supplied as a lyophilized powder by APExBIO (SKU: A3617). It is soluble at ≥32 mg/mL in DMSO and ≥50.9 mg/mL in ethanol (with gentle warming); insoluble in water (APExBIO). Recommended storage is at -20°C; avoid long-term storage of solutions and minimize freeze-thaw cycles. For cell-based assays, typical working concentrations range from 10 nM (sensitive BRCA-1/-2 mutant lines) to ≥1,000 nM (normal epithelial cells). In animal models, oral dosing regimens should be based on published efficacious exposures (see olaparib.net). For combination studies (e.g., with ATRA or cisplatin), sequence and dosing must be carefully controlled (Mei et al., 2025).

This article updates and clarifies the detailed workflow and resistance management strategies relative to Strategic Horizons in PARP Inhibition: Guiding Translational Cancer Research with MK-4827, which provides broader strategic context.

Conclusion & Outlook

MK-4827 (Niraparib) is a validated, highly selective PARP-1/-2 inhibitor that underpins much of contemporary BRCA-mutant and DNA repair-deficient cancer research (APExBIO). Its unique pharmacological profile enables selective targeting of HR-deficient tumors, supports radiosensitization strategies, and provides a robust platform for elucidating DNA damage response pathways. As resistance mechanisms become better understood, combination regimens (e.g., with retinoids or chemotherapeutics) and improved workflow controls will further enhance the translational value of MK-4827. For detailed product information and validated protocols, refer to the MK-4827 (Niraparib) product page at APExBIO. This article extends previous reviews by emphasizing actionable guidance for translational workflows and resistance management, building upon strategic overviews such as Reimagining DNA Damage Repair: Strategic Insights for Translational Researchers.